Aurobindo Pharma on Friday said its wholly owned step-down subsidiary, Agile Pharma BV, has incorporated a new wholly owned subsidiary in France named Arrow Pharma Production SAS, marking another step in the company’s European expansion strategy.
The newly incorporated entity, Arrow Pharma Production SAS, was established on May 21, 2026. It is being set up through Agile Pharma BV, Netherlands, which is a wholly owned subsidiary of Aurobindo Pharma. As a result, the French entity will also function as a wholly owned step-down subsidiary of the Indian drugmaker.
The company stated that the primary objective behind this incorporation is to expand its manufacturing capabilities for generic formulations in France. This aligns with Aurobindo Pharma’s broader strategy of strengthening its footprint in regulated markets, particularly Europe, where demand for cost-effective generic medicines continues to rise.
From a financial standpoint, Aurobindo Pharma has committed an initial investment of EUR 100,000 towards the subsidiary. The capital is divided into 100,000 shares with a face value of EUR 1 each, and the subscription will be made entirely in cash. The company will hold 100% ownership in the newly formed entity.
Notably, the company clarified that no governmental or regulatory approvals are required for the incorporation, indicating a smooth and straightforward setup process.
Market participants are likely to view this development as a strategic step toward enhancing Aurobindo Pharma’s manufacturing and supply chain capabilities within the European Union. Establishing a local production base could also help the company navigate regulatory frameworks more efficiently and improve market responsiveness.
Shares of Aurobindo Pharma may remain in focus as investors assess the long-term benefits of this expansion, particularly in the context of rising global demand for generics and increasing emphasis on localized pharmaceutical manufacturing.